Active, not recruitingPhase 2NCT07199569
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Studying Human infection by orthopoxvirus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bavarian Nordic
- Intervention
- Jynneos(biological)
- Enrollment
- 970 enrolled
- Eligibility
- 18-49 years · All sexes
- Timeline
- 2025 – 2026
Study locations (10)
- Accellacare and McFarland Clinic, Ames, Iowa, United States
- Johnson County ClinTrials, LLC, Lenexa, Kansas, United States
- Rochester Clinical Research, Inc, Rochester, New York, United States
- Accellacare of Cary - Cary Medical Group, Cary, North Carolina, United States
- Accellacare Research of Salisbury, Salisbury, North Carolina, United States
- Accellacare of Charleston, Mt. Pleasant, South Carolina, United States
- Accellacare - Knoxville, Knoxville, Tennessee, United States
- Avacare, Austin, Texas, United States
- Avacare, Fort Worth, Texas, United States
- Velocity Clinical Research, Suffolk, Virginia, United States
Collaborators
ICON plc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07199569 on ClinicalTrials.govOther trials for Human infection by orthopoxvirus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06839989An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE3NCT06844487Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRCJean-Pierre Van geertruyden
- RECRUITINGNCT06885853Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN VaccineAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT06771479A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live VaccineShanghai Institute Of Biological Products
- ACTIVE NOT RECRUITINGPHASE2NCT06549530Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus InfectionsBavarian Nordic
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06366672Evaluating the Human Immune Response to the JYNNEOS VaccineWashington University School of Medicine
- RECRUITINGNANCT05627713Clinical and Biological Aspects of the MONKEYPOX DiseaseInstitut Pasteur